ProCE Banner Activity

Phase I MonumenTAL-1: GPCR5D x CD3 Bispecific Antibody Talquetamab in Relapsed/Refractory Multiple Myeloma

Slideset Download
Conference Coverage
The novel bispecific antibody talquetamab appears active and tolerable in heavily pretreated patients with relapsed/refractory multiple myeloma.

Released: December 20, 2021

Begin Activity

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

Daiichi Sankyo Inc

GlaxoSmithKline

Incyte Corporation

Jazz Pharmaceuticals Inc

Merck Sharp & Dohme Corp

Novartis Pharmaceuticals Corporation